For more information, refer to the full study in Nature Communications.
A study led by Dr. Peter Canoll's lab, in collaboration with researchers at Columbia University Irving Medical Center, ...
11 C-labeled analog of DASA-23 was applied to the orthotopic U87 and GBM39 patient-derived tumors in preclinical models of glioblastoma multiforme and to monitor the response of the PKM2 activator ...
within the most aggressive malignant primary brain tumor, the Glioblastoma multiforme (GBM), several studies could show that patients with GBM have significantly more senescent cancer cells and more ...